ACHC
BEARISH
$23.52
Live
Acadia Healthcare Company, Inc. · NASDAQ
Target $22.71
(-3.4%)
$11.43
52W Range
$31.04
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$2.17B
P/E
N/A
ROE
-41.0%
Profit margin
-33.3%
Debt/Equity
1.24
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
ACHC's Piotroski F-Score of 2/9 indicates severe financial distress, with weak profitability, declining earnings, and high leverage. The absence of an Altman Z-Score and negative ROE (-40.96%) raise significant bankruptcy risk concerns. Despite a modest forward P/E of 14.03 and strong recent earnings surprises, the company's negative profit margin (-33.29%) and massive year-over-year EPS decline (-89.1%) undermine its fundamentals. The stock's 5-year price drop of 61.4% and lack of dividend support further signal investor skepticism. Analysts recommend 'buy' but with limited conviction, as the underlying financial health remains fragile.
Key Strengths
Recent quarterly earnings have consistently beaten estimates (3/4 in last 4 quarters)
Strong average earnings surprise of 206.53% over the last 4 quarters
Positive revenue growth of 6.10% YoY, outpacing many peers
Relatively low Price/Sales ratio of 0.65, suggesting potential undervaluation on a revenue basis
Healthy gross margin of 41.48% indicates solid operational efficiency in core services
Key Risks
Piotroski F-Score of 2/9 signals extreme financial weakness and high distress risk
Negative profit margin (-33.29%) and ROE (-40.96%) reflect deep profitability issues
Debt/Equity ratio of 1.24 is elevated for a healthcare facility operator, especially with negative earnings
Massive year-over-year EPS decline (-89.1%) and Q/Q EPS drop (-90.3%) indicate deteriorating earnings momentum
No analyst target price data available beyond a single 'buy' recommendation, indicating low consensus
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
36
Weak
55
42
60
25
0
AI Verdict
Weak
Key drivers: Low Piotroski F-Score (2/9), Negative ROE and profit margin, High debt-to-equity ratio, Declining earnings trends, Lack of intrinsic value metrics
Confidence
85%
Value
55/100
Ref P/E, PEG, Graham Number
Positives
- Price/Sales of 0.65 is below 1.0, suggesting potential undervaluation on a revenue basis
- Forward P/E of 14.03 is below sector average (185.39)
- Price/Book of 1.09 is modest, not overvalued
Watchpoints
- No Graham Number or intrinsic value estimate available
- Negative earnings make P/E and PEG unreliable
- High leverage undermines valuation stability
Future
42/100
Ref Growth rates
Positives
- 6.10% YoY revenue growth indicates top-line expansion
- Recent earnings surprises suggest potential upside in future reporting
Watchpoints
- Year-over-year EPS growth is -89.1%, indicating severe earnings contraction
- Q/Q EPS growth is -90.3%, signaling worsening performance
- No forward earnings guidance or FCF data available
Past
60/100
Ref Historical trends
Positives
- 3 out of last 4 quarters beat earnings estimates
- Average earnings surprise of 206.53% over last 4 quarters
- Consistent revenue growth over multiple quarters
Watchpoints
- Negative ROE and profit margin persist across multiple periods
- 5-year stock return of -61.4% reflects long-term underperformance
- Historical earnings volatility and inconsistency
Health
25/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 1.55 and quick ratio of 1.29 indicate short-term liquidity adequacy
- Operating margin of 5.80% shows some operational profitability
Watchpoints
- Piotroski F-Score of 2/9 is extremely low, indicating financial distress
- No Altman Z-Score available, but negative ROE and high leverage suggest distress risk
- Negative ROE (-40.96%) and negative profit margin (-33.29%) are red flags
- Debt/Equity of 1.24 is high for a company with negative earnings
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio available
- Payout ratio is 0.00%
- Dividend strength is 0/100
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$23.52
Analyst Target
$22.71
Upside/Downside
-3.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ACHC and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ACHC
Acadia Healthcare Company, Inc.
Primary
|
-61.4% | -66.0% | -16.5% | +8.2% | +51.5% | -8.2% |
|
PAHC
Phibro Animal Health Corporation
Peer
|
+144.3% | +265.7% | +224.4% | +40.4% | +2.6% | -8.8% |
|
BHC
Bausch Health Companies Inc.
Peer
|
-78.1% | -29.4% | -24.3% | -12.7% | -17.7% | -15.3% |
|
AHG
Akso Health Group
Peer
|
+24.4% | +547.7% | +88.2% | +30.8% | +77.3% | +85.2% |
|
DAWN
Day One Biopharmaceuticals, Inc.
Peer
|
-8.7% | +69.0% | +205.7% | +189.6% | +0.6% | +0.1% |
ACH
Acadia Healthcare Company, Inc.
Primary
5Y
-61.4%
3Y
-66.0%
1Y
-16.5%
6M
+8.2%
1M
+51.5%
1W
-8.2%
PAH
Phibro Animal Health Corporation
Peer
5Y
+144.3%
3Y
+265.7%
1Y
+224.4%
6M
+40.4%
1M
+2.6%
1W
-8.8%
BHC
Bausch Health Companies Inc.
Peer
5Y
-78.1%
3Y
-29.4%
1Y
-24.3%
6M
-12.7%
1M
-17.7%
1W
-15.3%
AHG
Akso Health Group
Peer
5Y
+24.4%
3Y
+547.7%
1Y
+88.2%
6M
+30.8%
1M
+77.3%
1W
+85.2%
DAW
Day One Biopharmaceuticals, Inc.
Peer
5Y
-8.7%
3Y
+69.0%
1Y
+205.7%
6M
+189.6%
1M
+0.6%
1W
+0.1%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
14.03
PEG Ratio
N/A
P/B Ratio
1.09
P/S Ratio
0.65
EV/Revenue
1.47
EV/EBITDA
8.46
Market Cap
$2.17B
Profitability
Profit margins and return metrics
Profit Margin
-33.29%
Operating Margin
5.8%
Gross Margin
41.48%
ROE
-40.96%
ROA
4.22%
Growth
Revenue and earnings growth rates
Revenue Growth
+6.1%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.24
Moderate
Current Ratio
1.55
Good
Quick Ratio
1.29
Good
Cash/Share
$1.45
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-11
$N/A
2026-02-25
$0.07
+593.1% surprise
2025-11-05
$0.72
+9.2% surprise
2025-08-05
$0.83
+17.4% surprise
Healthcare Sector Comparison
Comparing ACHC against 393 companies in the Healthcare sector
(24 bullish, 129 neutral, 240 bearish)
Return on Equity (ROE)
-40.96%
This Stock
vs
-101.52%
Sector Avg
-59.6%
(Below Avg)
Profit Margin
-33.29%
This Stock
vs
-12.47%
Sector Avg
+167.0%
(Superior)
Debt to Equity
1.24
This Stock
vs
3.4
Sector Avg
-63.5%
(Less Debt)
Revenue Growth
6.1%
This Stock
vs
124.21%
Sector Avg
-95.1%
(Slower)
Current Ratio
1.55
This Stock
vs
4.56
Sector Avg
-66.0%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ACHC
Acadia Healthcare Company, Inc.
|
BEARISH | $2.17B | - | -41.0% | -33.3% | $23.52 | |
|
PAHC
Phibro Animal Health Corporation
|
NEUTRAL | $2.18B | 23.84 | 31.8% | 6.3% | $53.88 | Compare |
|
BHC
Bausch Health Companies Inc.
|
BEARISH | $2.19B | 6.79 | 563.2% | 3.6% | $5.91 | Compare |
|
AHG
Akso Health Group
|
BEARISH | $2.14B | - | -68.3% | -% | $2.5 | Compare |
|
DAWN
Day One Biopharmaceuticals, Inc.
|
NEUTRAL | $2.22B | - | -22.7% | -67.8% | $21.46 | Compare |
ACHC
Acadia...
BEARISH
Mkt Cap
$2.2B
P/E
-
ROE
-41.0%
Price
$23.52
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-10-27 | YOUNG TODD S | Chief Financial Officer | Stock Award | 48,445 | - |
YOUNG TODD S
Chief Financial Officer
2025-10-27
48,445 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
14 analysts
Barclays
2026-03-03
Equal-Weight
Equal-Weight
Leerink Partners
2026-02-26
Market Perform
Market Perform
UBS
2026-02-26
Buy
Buy
TD Cowen
2026-02-26
Buy
Buy
RBC Capital
2026-02-26
Outperform
Outperform
Guggenheim
2026-02-23
Buy
Buy
Jefferies
2026-01-22
Buy
Hold
TD Cowen
2026-01-16
Buy
Buy
RBC Capital
2026-01-14
Outperform
Outperform
Mizuho
2025-12-18
Neutral
Neutral
Past News Coverage
Recent headlines mentioning ACHC from our newsroom.
Newest → oldest
No matching news yet.